Evidence map›Paper›PMID 41375182›Full record

ArticleMolecules (Basel, Switzerland)2025

In Silico Analysis of C

Vasyl Hurmach, Viacheslav Karaushu, Svitlana Prylutska, Zinaida Klestova, Sergiy Vyzhva, Yuriy Prylutskyy, Uwe Ritter, Vasil Garamus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vasyl HurmachInstitute of Molecular Biology and Genetics, National Academy of Science (NAS) of Ukraine, 03143 Kyiv, Ukraine.
Viacheslav KaraushuTaras Shevchenko National University of Kyiv, 01601 Kyiv, Ukraine.
Svitlana PrylutskaNational University of Life and Environmental Science of Ukraine, 03041 Kyiv, Ukraine.
Zinaida KlestovaThe Institute for Medical Virology and Epidemiology of Viral Diseases, 72076 Tübingen, Germany.ORCID 0000-0003-0771-7808
Sergiy VyzhvaTaras Shevchenko National University of Kyiv, 01601 Kyiv, Ukraine.
Yuriy PrylutskyyTaras Shevchenko National University of Kyiv, 01601 Kyiv, Ukraine.
Uwe RitterTechnical University of Ilmenau, 98693 Ilmenau, Germany.ORCID 0000-0002-9315-4863
Vasil GaramusHelmholtz-Zentrum Hereon, 21502 Geesthacht, Germany.ORCID 0000-0001-9315-4188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent global spread of the SARS-CoV-2 pathogen, which causes COVID-19, and its rapid mutation, requires the fast development of effective preventive and treatment measures. According to WHO reports, over 778 million confirmed cases of COVID-19 have been reported, including approximately 7 million deaths. The androgen-regulated cell-surface serine protease TMPRSS2 interacts with the SARS-CoV-2 spike protein. Therefore, directly inhibiting TMPRSS2 will negatively impact the activation of coronaviruses and, consequently, disease progression. That is why TMPRSS2 is a very important target in current drug discovery. On the other hand, it is known that C

Indexed as

FullerenesSerine EndopeptidasesAntiviral AgentsBinding SitesComputer SimulationCOVID-19HumansMolecular Docking SimulationMolecular Dynamics SimulationPandemicsProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusAntiviral Agentsfullerene C60FullerenesSerine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TMPRSS2 protein, humanbinding sitesC60 fullerenecomputer simulationCOVID-19TMPRSS2

Identifiers

PMID41375182
PMCPMC12693319

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.